Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases [Seeking Alpha]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Seeking Alpha
Tanruprubart's Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument's Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market. I estimate fair value at $14.50/share, with 2026 as a pivotal year for clarity on the tanruprubart filing process, clinical vonaprument milestones, and possible commercial partnerships. jtamm/iStock via Getty Images Although systemic complement-mediated diseases are, fortunately, relatively rare, there is a wider range of diseases where complement overactivation plays a significant role, and these are often hard-to-treat diseases with serious quality of life implications. Annexon ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Annexon (NASDAQ:ANNX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead [Yahoo! Finance]Yahoo! Finance
- Annexon (NASDAQ:ANNX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
ANNX
Earnings
- 11/10/25 - Miss
ANNX
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/21/26 - Form SCHEDULE
- 1/14/26 - Form 8-K
- ANNX's page on the SEC website